IMNN files 8-K furnishing Q2 2025 release and webcasted investor call

Rhea-AI Filing Summary

Event summary: On August 5, 2025 Imunon, Inc. (IMNN) furnished a press release reporting financial results for the quarter ended June 30, 2025 as Exhibit 99.1. The company had announced on July 29, 2025 that it would hold a conference call on August 5, 2025 to discuss those results; the call was webcast at http://www.imunon.com.

The 8-K clarifies the furnished information is not "filed" under Section 18 of the Exchange Act and contains forward-looking statements subject to a cautionary note in the press release. Exhibits listed are 99.1 (press release) and 104 (Interactive Data). The report is signed by CFO Kimberly Graper and lists principal offices at 997 Lenox Drive, Suite 100, Lawrenceville, NJ 08648-2311 with phone (609) 896-9100.

Positive

• Press release for Q2 2025 results furnished as Exhibit 99.1
• Company scheduled and webcasted a conference call for investors (Aug 5, 2025)
• Filing includes Interactive Data (Exhibit 104), suggesting XBRL tagging

Negative

• The 8-K text does not present any financial figures or metrics; investors must refer to Exhibit 99.1 for results
• Information is furnished, not filed, limiting Section 18 liability and related investor protections

Insights

Financial Analyst

TL;DR: Routine earnings disclosure furnished via 8-K; investors should review Exhibit 99.1 for material results.

The filing is a standard Section 2.02 8-K furnishing a press release with Q2 2025 results and scheduling an investor call. As furnished information, it carries the company\'s cautionary forward-looking language and is explicitly not "filed" under Section 18, limiting SEC liability. For valuation or trading decisions, the press release (Exhibit 99.1) must be consulted for revenue, EPS, guidance, or material nonrecurring items; the 8-K text itself contains no financial metrics.

Corporate Governance Expert

TL;DR: Administrative 8-K disclosure; governance impact is neutral but complies with timely investor communication practices.

The company correctly furnished its earnings release and webcast details and disclosed the legal status of the furnished materials. Signature by the CFO on the filing and inclusion of the interactive data exhibit (104) indicate procedural compliance. There are no governance red flags or executive changes disclosed in this report.

false 0000749647 0000749647 2025-08-05 2025-08-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 5, 2025

Imunon, Inc.

(Exact name of registrant as specified in its Charter)

Delaware		001-15911		52-1256615
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

997 Lenox Drive, Suite 100, Lawrenceville, NJ		08648-2311
(Address of principal executive offices)		(Zip Code)

(609) 896-9100

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

	☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common stock, par value $0.01 per share		IMNN		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 5, 2025, Imunon, Inc. issued a press release reporting its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

On July 29, 2025, Imunon, Inc. announced it would hold a conference call on August 5, 2025 to discuss its financial results for the quarter ended June 30, 2025 and provide a business update. The conference call will also be broadcast live on the internet at http://www.imunon.com.

The information in this report, including the exhibit hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. Such information shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by Imunon, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.

The press release contains forward-looking statements which involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Please refer to the cautionary note in the press release regarding these forward-looking statements.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release dated August 5, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	IMUNON INC.
Dated: August 5, 2025	By:	/s/ Kimberly Graper
		Kimberly Graper
		Chief Financial Officer

FAQ

What did Imunon (IMNN) disclose in the 8-K filed August 5, 2025?

The 8-K states Imunon furnished a press release reporting Q2 2025 results (quarter ended June 30, 2025) and noted a conference call on August 5, 2025.

Where can I find the detailed Q2 2025 results for IMNN?

The detailed results are provided in the press release furnished as Exhibit 99.1 to the 8-K; consult that exhibit for revenue, EPS, and guidance.

Was the earnings call for IMNN webcast and where?

Yes, the company announced the conference call on July 29, 2025 and webcast the call on http://www.imunon.com on August 5, 2025.

Does the 8-K constitute "filed" disclosure under the Exchange Act?

No. The 8-K explicitly states the information is furnished and shall not be deemed "filed" under Section 18 of the Exchange Act.

Who signed the 8-K for Imunon and when?

The report is signed by CFO Kimberly Graper and dated August 5, 2025.